Related Experiment Video
Updated: Mar 27, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.5K
IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes
1The Esplanade Surgery, 19 The Esplanade, Ryde PO33 2EH, Isle of Wight, UK.
Primary Care Diabetes
|January 19, 2016
Summary
Intensive type 2 diabetes treatment can cause side effects. Combining basal insulin and glucagon-like peptide-1 receptor agonists (GLP-1RAs) offers an alternative, with IDegLira providing a convenient co-formulation.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Type 2 diabetes (T2D) management aims to reduce hyperglycemia and microvascular risks.
- Intensive glycemic control treatments can lead to adverse effects like hypoglycemia and weight gain.
- Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and basal insulin offer complementary mechanisms for T2D management.
Purpose of the Study:
- To review the rationale for combining GLP-1RAs and basal insulin in T2D treatment.
- To present clinical data on IDegLira, a co-formulated basal insulin (insulin degludec) and GLP-1RA (liraglutide).
Main Methods:
- Review of existing literature and clinical trial data.
- Analysis of the pharmacological synergy between insulin degludec and liraglutide.
- Evaluation of IDegLira's efficacy and safety profile.
Main Results:
- Combination therapy with GLP-1RAs and basal insulin provides an alternative to basal-bolus regimens.
- IDegLira offers a simplified daily injection regimen for T2D patients.
- Clinical data supports the efficacy and tolerability of this co-formulation.
Conclusions:
- The combination of basal insulin and GLP-1RAs is a viable therapeutic strategy for T2D.
- IDegLira represents a significant advancement in simplifying treatment regimens.
- Further research should explore long-term outcomes and broader patient populations.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
1.2K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.2K
01:27Insulin Formulations: Types and Delivery
1.1K
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
1.1K
01:06Oral Hypoglycemic Agents: Glinides
932
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
932
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:23Dipeptidyl Peptidase 4 Inhibitors
1.0K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.0K
01:22Diabetes Mellitus: Overview and Type I Subtype
5.9K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.9K